EDA Stock Overview Develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
EDAP TMS S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for EDAP TMS Historical stock prices Current Share Price US$2.08 52 Week High US$7.70 52 Week Low US$2.04 Beta 0.34 1 Month Change -10.34% 3 Month Change -19.38% 1 Year Change -53.36% 3 Year Change -55.93% 5 Year Change -44.68% Change since IPO 41.88%
Recent News & Updates
Edap Tms S.A. Provides HIFI Study Publication Demonstrates Positive Outcomes with Focal One Robotic HIFU Versus Surgery in the Management of Prostate Cancer Dec 05
Third quarter 2024 earnings released: €0.17 loss per share (vs €0.11 loss in 3Q 2023) Nov 08
EDAP TMS S.A. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
EDAP TMS S.A. Announces First Patients Treated in Phase I/Ii Study Evaluating Focal One Robotic Hifu for the Treatment of Benign Prostatic Hyperplasia (Bph) Oct 01
New minor risk - Market cap size Oct 01
Second quarter 2024 earnings released: €0.17 loss per share (vs €0.13 loss in 2Q 2023) Aug 29 See more updates
Edap Tms S.A. Provides HIFI Study Publication Demonstrates Positive Outcomes with Focal One Robotic HIFU Versus Surgery in the Management of Prostate Cancer Dec 05
Third quarter 2024 earnings released: €0.17 loss per share (vs €0.11 loss in 3Q 2023) Nov 08
EDAP TMS S.A. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
EDAP TMS S.A. Announces First Patients Treated in Phase I/Ii Study Evaluating Focal One Robotic Hifu for the Treatment of Benign Prostatic Hyperplasia (Bph) Oct 01
New minor risk - Market cap size Oct 01
Second quarter 2024 earnings released: €0.17 loss per share (vs €0.13 loss in 2Q 2023) Aug 29
EDAP TMS S.A. Announces Resignation of Marc Oczachowski as Chairman of Board of Directors, Effective September 30, 2024 Aug 28
New minor risk - Share price stability Aug 12
EDAP TMS S.A. to Report Q2, 2024 Results on Aug 28, 2024 Aug 07
EDAP TMS S.A. Announces Interim Results from Phase 3 Study Evaluating Robotic Hifu for the Treatment of Deep Infiltrating Endometriosis Jul 20
EDAP TMS S.A. Appoints Fran Schulz to Board of Directors Jul 08
First quarter 2024 earnings released: €0.12 loss per share (vs €0.20 loss in 1Q 2023) May 18
EDAP TMS S.A. to Report Q1, 2024 Results on May 16, 2024 May 03
Full year 2023 earnings released: €0.57 loss per share (vs €0.085 loss in FY 2022) Mar 28
EDAP TMS S.A. to Report Q4, 2023 Results on Mar 27, 2024 Mar 14
EDAP TMS SA Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis Mar 05
EDAP TMS S.A. Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One Hifu Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis Feb 02 EDAP TMS S.A. Appoints Ken Mobeck as Chief Financial Officer
Less than half of directors are independent Dec 14
EDAP TMS S.A. Announces Board Changes Dec 07
Third quarter 2023 earnings released: €0.11 loss per share (vs €0 in 3Q 2022) Nov 10
EDAP TMS S.A. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
New minor risk - Profitability Aug 25
Second quarter 2023 earnings released: €0.13 loss per share (vs €0.055 profit in 2Q 2022) Aug 25
EDAP TMS S.A. Announces Board Changes Aug 25
New major risk - Revenue and earnings growth Aug 25
EDAP TMS S.A. to Report Q2, 2023 Results on Aug 24, 2023 Aug 11
Insufficient new directors Jul 01
EDAP TMS S.A., Annual General Meeting, Jun 30, 2023 Jun 07
First quarter 2023 earnings released: €0.20 loss per share (vs €0.011 profit in 1Q 2022) May 18
EDAP TMS S.A. to Report Q1, 2023 Results on May 17, 2023 May 04
Full year 2022 earnings released: €0.085 loss per share (vs €0.022 profit in FY 2021) Mar 31
EDAP TMS SA Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound for the Treatment of Rectal Endometriosis Feb 01
Now 23% undervalued Jan 03
Now 22% undervalued Dec 15
EDAP TMS S.A. Announces Approval to Initiate Randomized Clinical Trial Evaluating Focal One® as a Potential Treatment for Rectal Deep Infiltrating Endometriosis Dec 01
Third quarter 2022 earnings released Nov 18
EDAP TMS S.A. to Report Q3, 2022 Results on Nov 16, 2022 Nov 03
EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million. Sep 24 EDAP TMS S.A. has completed a Follow-on Equity Offering in the amount of $20.000003 million. Sep 23
Second quarter 2022 earnings released: EPS: €0.055 (vs €0.013 loss in 2Q 2021) Aug 26
EDAP TMS S.A. to Report Q2, 2022 Results on Aug 24, 2022 Aug 04
EDAP TMS S.A., Annual General Meeting, Jun 30, 2022 Jun 11
First quarter 2022 earnings released: EPS: €0.011 (vs €0.026 in 1Q 2021) May 19
EDAP TMS S.A. to Report Q1, 2022 Results on May 17, 2022 May 12
EDAP TMS S.A. to Showcase Its Focal One® Platform At the Annual Meeting of the American Urological Association May 06
Full year 2021 earnings released: EPS: €0.021 (vs €0.058 loss in FY 2020) Apr 01
EDAP TMS S.A. to Report Q4, 2021 Results on Mar 30, 2022 Mar 23
EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers Jan 14
Third quarter 2021 earnings released: €0.03 loss per share (vs €0.034 loss in 3Q 2020) Nov 19
Mega Elektroniikka Oy agreed to acquire a 25% stake in Technomed Medical Systems S.A from EDAP TMS S.A. (NasdaqGM : EDAP). Sep 02
Second quarter 2021 earnings released: €0.013 loss per share (vs €0.006 loss in 2Q 2020) Aug 26
EDAP TMS S.A. Provides Unaudited Earnings Guidance for the Second Quarter of 2021 Aug 06
First quarter 2021 earnings released: EPS €0.026 (vs €0.045 loss in 1Q 2020) May 13
EDAP TMS S.A. Provides Earnings Guidance for the First Quarter Ended March 31, 2021 Apr 24
Full year 2020 earnings released: €0.058 loss per share (vs €0.052 profit in FY 2019) Apr 02
New 90-day high: €6.50 Jan 26
EDAP Announces Positive Interim Results of French Urology Association Sponsored Clinical Study Comparing HIFU to Radical Prostate Surgery Jan 15
New 90-day high: €4.60 Jan 09
New 90-day high: €4.20 Dec 24
Third quarter 2020 earnings released: €0.034 loss per share Nov 20
Revenue beats expectations Nov 20
EDAP TMS SA Announces the Company Signs an Exclusive Distribution Agreement with AB Medica Nov 18
EDAP TMS S.A. to Report Q3, 2020 Results on Nov 18, 2020 Nov 10
New 90-day high: €4.06 Oct 21
New 90-day high: €3.98 Sep 28
New 90-day high - €3.00 Aug 28
First half earnings released Aug 28
EDAP TMS S.A. to Report Q2, 2020 Results on Aug 26, 2020 Aug 20
New 90-day high - €2.80 Jul 18 Shareholder Returns EDA DE Medical Equipment DE Market 7D 1.0% -3.3% -2.0% 1Y -53.4% -8.5% 6.9%
See full shareholder returns
Return vs Market: EDA underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is EDA's price volatile compared to industry and market? EDA volatility EDA Average Weekly Movement 8.1% Medical Equipment Industry Average Movement 6.7% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: EDA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EDA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
Show more EDAP TMS S.A. Fundamentals Summary How do EDAP TMS's earnings and revenue compare to its market cap? EDA fundamental statistics Market cap €78.08m Earnings (TTM ) -€22.12m Revenue (TTM ) €63.41m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EDA income statement (TTM ) Revenue €63.41m Cost of Revenue €37.39m Gross Profit €26.02m Other Expenses €48.14m Earnings -€22.12m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.60 Gross Margin 41.04% Net Profit Margin -34.88% Debt/Equity Ratio 15.2%
How did EDA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 23:58 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources EDAP TMS S.A. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew D'Silva B. Riley Securities, Inc. null null CG Capital Swayampakula Ramakanth H.C. Wainwright & Co.
Show 4 more analysts 
